Demonstrates effective drug discovery via generative AI in accessible settings, suggesting improved outcomes for smaller labs.
drug-like molecules, but current computational approaches are fragmented across multiple tools and require enterprise-grade hardware, thus creating a sort of "computational divide" that excludes many academic groups and smaller laboratories. We introduce in this study a unified end-to-end Generative AI Assistant, specifically designed for constrained hardware environments, optimized to run on widely available consumer-grade GPUs like the NVIDIA GTX 1650 with 4 GB VRAM. With our system, we integrated a lightweight LSTM-based generative model using SELFIES tokenization to ensure 100% syntactic validity, a multi-task XGBoost classifier for toxicity prediction across 12 biological assays, hybrid property prediction with molecular fingerprints, and an API-based module for 3D protein structure prediction via ESMFold. Using benchmark testing, we have established a robust performance level with a reliable convergence of our generative model in conjunction with an overall decrease in training loss from 2.15 to 1.19 and a stable validation loss of 1.43, as well as a weighted average AUC of 0.790 for our toxicity classifier. Toxic-class recall significantly increased after threshold tuning, improving the framework's appropriateness for early-stage safety screening applications. In addition, the analysis of chemical space validates the model's ability to generate previously unexplored novel molecules that possess desirable drug-like characteristics (mean LogP = 2.04) and to enhance safety, we are integrating both ML-based toxicity screening and a rule-based PAINS filtering into a novel hybrid prototype. As an additional contribution to overall accessibility, we also developed and tested a CPU fallback feature to allow for automatic fallback of the generative model in instances of hardware incompatibility. Together these contributions enable the efficient and cost-effective democratization of modern drug discovery workflows on affordable hardware (93% reduction in infrastructure costs) without sacrificing the scientific integrity or predictive capability of our developed models.
No takes yet. Share an insight, caveat, or question.
Bhatia et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: